← 29 September 2026's Current Affairs · Karnataka KPSC Prelims ★★★☆☆ Mains ★★☆☆☆
Karnataka Health Minister Flags Steep Markup on Critical Drugs
വാർത്തയിൽ എന്തുകൊണ്ട്?
Up to 70 times procurement cost: the MRP versus net acquisition price gap GS-II drug regulation answers need
Karnataka's Health Minister said critical drugs are marked up to 70 times procurement cost and sought a national pricing-transparency study.
Why it matters: Karnataka-specific
What you need to know
2 മിനിറ്റ്
Karnataka's Health Minister said certain cancer, kidney and AIDS drugs are being sold at up to 70 times their procurement cost.
He sought a national study comparing the printed MRP, the manufacturer or importer's price, the hospital's net acquisition price, and the price ultimately billed to patients.
The remarks point to wide gaps in drug-pricing transparency across the supply chain for critical medicines.
ഉറവിടങ്ങൾ: Topper IAS editorial (PIB / The Hindu / Indian Express)
പ്രധാന വസ്തുതകൾ
Remember these
- Karnataka's Health Minister said certain cancer, kidney and AIDS drugs sell at up to 70 times their procurement cost.
- He sought a national study comparing four prices: printed MRP, manufacturer/importer price, hospital's net acquisition price, and price billed to the patient.
- MRP (Maximum Retail Price) is the highest price at which a packaged product can be sold to the consumer.
- Drug price regulation in India is administered nationally by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs (Prices Control) Order.
- Health is a State subject, but drug pricing policy is shaped at the Union level.
പ്രിലിംസ് · മെയിൻസ്
How the exam will ask it
പ്രിലിംസ്
- MRP is the maximum price a retailer may charge a consumer for a packaged commodity; it is printed on the pack.
- The National Pharmaceutical Pricing Authority (NPPA) fixes and revises prices of scheduled drugs under the Drugs (Prices Control) Order.
- Net acquisition price is what a hospital actually pays to procure a drug, which can be far below the printed MRP.
- A gap between hospital acquisition price and the price billed to patients is a pricing-transparency issue, not necessarily a breach of MRP.
മെയിൻസ്
GS-II (Governance, health policy): opaque price chains let critical drugs be billed far above procurement cost, hurting patients with cancer, kidney disease and HIV/AIDS. The policy tools are MRP printing, NPPA price control under the DPCO and trade-margin rationalisation. The way forward is a national study of the full price chain, mandatory disclosure of acquisition prices and stronger price monitoring, balanced with Centre-State coordination on health.
Quick recall
Answer before you reveal
With reference to remarks by Karnataka's Health Minister on drug pricing, consider the following statements:
- Certain cancer, kidney and AIDS drugs are being sold at up to 70 times their procurement cost.
- He sought a national study comparing only the manufacturer's price with the hospital's net acquisition price.
Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
ഉത്തരം കാണിക്കൂ
ഉത്തരം: A — Correct: 1 only — the Minister said these drugs sell at up to 70 times procurement cost; he sought a broader national study comparing printed MRP, manufacturer/importer price, hospital's net acquisition price and the price billed to patients — not just two of these — making statement 2 wrong. • 2 only — wrong: statement 1 is true. • Both 1 and 2 — wrong: statement 2 understates the study's scope. • Neither 1 nor 2 — wrong: statement 1 is true.
Convert this topic into marks
Today's 10-MCQ test · instant analysis · Powered by AdaptIQ